With the advancement of nanotechnology, several nanoparticles have been synthesized as antimicrobial agents by utilizing biologically derived materials. In most cases, the materials used for the synthesis of nanoparticles from natural sources are extracts. Natural extracts contain a wide range of bioactive components, making it difficult to pinpoint the exact component responsible for nanoparticle synthesis. Furthermore, the bioactive component present in the extract changes according to numerous environmental factors. As a result, the current work intended to synthesize gold (AuNPs) and zinc oxide (ZnONPs) nanoparticles using pure phloroglucinol (PG). The synthesized PG-AuNPs and PG-ZnONPs were characterized using a UV–Vis absorption spectrophotometer, FTIR, DLS, FE-TEM, zeta potential, EDS, and energy-dispersive X-ray diffraction. The characterized PG-AuNPs and PG-ZnONPs have been employed to combat the pathogenesis of Pseudomonas aeruginosa. P. aeruginosa is recognized as one of the most prevalent pathogens responsible for the common cause of nosocomial infection in humans. Antimicrobial resistance in P. aeruginosa has been linked to the development of recalcitrant phenotypic characteristics, such as biofilm, which has been identified as one of the major obstacles to antimicrobial therapy. Furthermore, P. aeruginosa generates various virulence factors that are a major cause of chronic infection. These PG-AuNPs and PG-ZnONPs significantly inhibit early stage biofilm and eradicate mature biofilm. Furthermore, these NPs reduce P. aeruginosa virulence factors such as pyoverdine, pyocyanin, protease, rhamnolipid, and hemolytic capabilities. In addition, these NPs significantly reduce P. aeruginosa swarming, swimming, and twitching motility. PG-AuNPs and PG-ZnONPs can be used as control agents for infections caused by the biofilm-forming human pathogenic bacterium P. aeruginosa.

No abstract

The emergence of antibiotic resistance in microbial pathogens necessitates the development of alternative ways to combat the infections that arise. The current study used nanotechnology as an alternate technique to control virulence characteristics and biofilm development in Pseudomonas aeruginosa and Staphylococcus aureus. Furthermore, based on the acceptance and biocompatibility of the probiotic bacteria, we chose a lactic acid bacteria (LAB) for synthesizing two types of metallic nanoparticles (NPs) in this study. Using molecular techniques, the LAB strain C1 was isolated from Kimchi food samples and identified as Lactiplantibacillus sp. strain C1. The prepared supernatant from strain C1 was used to produce gold nanoparticles (AuNPs) and silver nanoparticles (AgNPs). C1-AuNPs and C1-AgNPs were characterized physiochemically using a variety of instruments. C1-AuNPs and C1-AgNPs had spherical shapes and sizes of 100.54 ± 14.07 nm (AuNPs) and 129.51 ± 12.31 nm (AgNPs), respectively. C1-AuNPs and C1-AgNPs were discovered to have high zeta potentials of −23.29 ± 1.17 and −30.57 ± 0.29 mV, respectively. These nanoparticles have antibacterial properties against several bacterial pathogens. C1-AuNPs and C1-AgNPs significantly inhibited the initial stage biofilm formation and effectively eradicated established mature biofilms of P. aeruginosa and S. aureus. Furthermore, when P. aeruginosa was treated with sub-MIC levels of C1-AuNPs and C1-AgNPs, their different virulence features were significantly reduced. Both NPs greatly inhibited the hemolytic activity of S. aureus. The inhibition of P. aeruginosa and S. aureus biofilms and virulence features by C1-AuNPs and C1-AgNPs can be regarded as viable therapeutic strategies for preventing infections caused by these bacteria.

No abstract

No abstract